Federal government announces positive changes to drug pricing regulations

August 9, 2019

Canada’s unions applaud today’s announcement by the federal government of new measures updating Canada’s drug-pricing regulations.

“Many life-saving medicines are unaffordable. This new framework will better protect Canadians from skyrocketing drug prices by lowering the cost of brand name medicines,” said CLC President Hassan Yussuff. “This is a good step towards a universal public pharmacare program in Canada.”

Canada currently compares prices with the US and Switzerland—two countries with some of the world’s highest drug prices—when setting its maximum prices for patented drugs. These new regulations no longer require consideration of US and Swiss pricing, instead allowing the Patented Medicine Prices Review Board (PMPRB) to set maximum prices for patented drugs based on other countries with economies and health-care systems similar to Canada.

The updated framework also provides better reporting on drug prices including list prices and discounts offered to third parties like insurance companies. The PMPRB will also have the authority to determine whether drug prices correspond to value to patients and to the healthcare system.

The existing framework used by the PMPRB has not adequately protected Canadians from excessively high prices for patented medicines over the last 30 years. Since 1987, prescription drug costs in Canada have increased at an average annual rate of 7.3%, or over 3 times the inflation rate.

“Canadians have been paying some of the highest prices for patented medicines in the world because the old regulations allowed big pharmaceutical companies to set their prices based on market evaluations, and not on what individuals could actually afford,” said Yussuff.

“Big pharmaceutical companies have continued to renege on their promises to invest 10% of sales in research and development each year, and to introduce new drugs that had substantial or breakthrough therapeutic benefit to Canadians,” said Yussuff.

In 2017, the investment of big pharmaceutical companies was the lowest it has ever been in 30 years—a paltry 4.6%—and nine-in-ten new-patented medicines offered slight or no improvement in therapeutic benefit over existing therapies.

Tags: Pharmacare

Related Articles

Working families have a lot at stake this election

By Hassan Yussuff You can be forgiven if you’ve avoided thinking about the upcoming federal election all summer, but Labour Day is here. That means it’s time to return to the fall routine and start thinking about how you are going to cast your ballot. You may have seen politicians working the barbecue circuit, vying for the support of workers…
Read More

Labour Day 2019: Unions seek to put fairness on the ballot

This Labour Day, Canada’s unions are launching a campaign to make fairness a ballot box question in the October federal election. That means unions will be calling on Canadian workers to vote for candidates who support universal pharmacare, retirement security, climate action, equity and inclusion, and good jobs for everyone. “Over the last four years, our work has resulted in…
Read More

Universal pharmacare should be an easy pill to swallow

By Hassan Yussuff, as published in the Toronto Sun. Finally, some good news for the millions of Canadians who have to choose between paying for groceries or their prescription medications. Canada’s Advisory Council on the Implementation of National Pharmacare has laid out a clear path for public, single-payer, universal pharmacare in its final report. “The time for universal, single-payer, public…
Read More